Regeneron stock price target raised to $640 from $600 at BMO Capital

Regeneron Pharmaceuticals (REGN) reported significantly stronger-than-expected Q2 2025 earnings and revenue, prompting multiple analyst upgrades and increased price targets from firms including BMO Capital, Bernstein SocGen, and Leerink Partners. Analysts highlighted the company's progress in its Eylea franchise, upcoming clinical milestones, and robust financial health as key drivers for a positive outlook, despite acknowledging some lingering regulatory hurdles. The stock is widely viewed as undervalued with a promising long-term growth trajectory.

Analysis

Regeneron Pharmaceuticals (REGN) demonstrated significant operational momentum in its second quarter of 2025, reporting an earnings per share of $12.89 that surpassed analyst forecasts by over 51% and revenue of $3.68 billion that beat consensus estimates by 11%. This performance, described by BMO Capital as a "much-needed clean quarter," has triggered a wave of positive analyst revisions, with firms like BMO, Bernstein, and Leerink raising price targets to $640, $753, and $645, respectively, all while maintaining Outperform ratings. The strong results are largely attributed to progress in regaining competitive positioning for the critical Eylea franchise. Despite this, the stock's valuation is weighed down by past clinical and regulatory missteps. The company's financial health remains robust, evidenced by a current ratio of 4.6 and a P/E ratio of 13.7, which, according to InvestingPro analysis, suggests the stock is undervalued. Key future catalysts include upcoming LAG3 first-line Melanoma data expected in late 2025 or early 2026 and a planned head-to-head trial for Lynozyfic against Darzalex, which support a long-term growth outlook projecting a 10% EPS compound annual growth rate through 2030.

Key Decisions for Investors

• Given the substantial Q2 2025 earnings beat and multiple analyst upgrades, investors could consider the company's P/E ratio of 13.7 an attractive valuation entry point for a fundamentally strong biotech firm.
• It is critical to monitor upcoming clinical and regulatory milestones, particularly the LAG3 melanoma data and progress on Eylea HD label expansions, as these are primary catalysts for future share price appreciation.
• Despite the positive quarter, investors should remain cautious of the acknowledged 'clinical and regulatory missteps' which continue to pose a risk and could introduce volatility to the stock.
• For those with a long-term horizon, the projected 7% revenue and 10% EPS compound annual growth rates through 2030 provide a basis for a buy-and-hold strategy, contingent on successful execution of the clinical pipeline.